Collegium Q1 revenue up 9% to $193.5M; JORNAY PM +36%; FY guidance reaffirmed; AZSTARYS deal on track

COLLEGIUM PHARMACEUTICAL, INC

2026-Q1 EPS reported $0.40 vs consensus $1.62 ▼ miss (-75.4%)

Product net revenue of $193.5M (+9% YoY); GAAP diluted EPS $0.40; adjusted EPS $1.76.
JORNAY PM net revenue $38.9M (+36% YoY); prescriptions rose 14% to >206,000.
Pain portfolio net revenue $154.6M (+4% YoY); Belbuca $52.6M, Xtampza ER $50.8M.
Reaffirmed FY 2026 guidance: product revenue $805-825M, adjusted EBITDA $455-475M.
Acquisition of AZSTARYS for $650M cash on track to close Q2 2026; $135M milestone potential.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2026 results: revenue $193.5 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2026
Revenue: $193.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress – Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of

View on SEC.gov

Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001628280-26-031694

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.